Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00345-0/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=covidalerts&utm_medium=email&_hsmi=276355044&_hsenc=p2ANqtz--bAjoNZsjlnYHI3zitrLTcW2gkwOTJqV28LrZ-huHVtP2IrwH4dujzWAQ77k-YiihOYDn6CxfkwgtPvQqvqJNKWQkVEw&utm_content=276317812&utm_source=hs_email